Reductionist biology risks eliminating interesting lead while in vivo screening is considered too slow and too expensive.
WatchFrog offers to incorporate in vivo significance to early in vitro stage of drug discovery and provides pharmaceutical companies with a unique methodology for developing new molecules:
- Target validation
- In vivo drug efficiency evaluation
- Design of new synthetic biology based pathological models
- Middle/ High throughput screening
- Monitoring principal and secondary non desired biological effect
- Endocrine regulations, neurotoxicity, disruption, neuro-developmental impairment cardiotoxicity, teratogenicity, immune response, malformation